DE
Investor Relations

Investment History

  • US$ 14M invested by Private Investors from 2012 (founders and VCs)
  • US$ 5M invested by CSO and Innovation Authorities (Non dilutive Grants).
  • In 2019 Max Herzberg and Yochai Richter acquired all shares of the VC group as a Management buy out
  • From 2019 the Company is funded by them on a need to spend basis
  • Going to Public Market and GEM for further major funding (Phase 2 and 3 for previous project and present application)
  • Main Shareholders committed to complementary funding if necessary.
  • Funding application to Horizon (EEC) : first application submitted on NMSC Phase 3 for VDA1102.

Vidac Pharma Holding PLC

Dr. Max Herzberg
      20-22 Wenlock Road
      London N1 7GU
      United Kingdom
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647
LEI: 875500BCH1T6XX5EUG13
ISIN: GB00BM9XQ619
WKN : A3DTUQ
Total number of issued shares is 51,625,062
Vidac - T9G
TRADING SYMBOL: T9G
WKN: A3DTUQ
ISIN: GB00BM9XQ619
LEI: 875500BCH1T6XX5EUG13

Financial Statements

31 December 2021 Financial Statement

Download

6 month financial statements 2022

Download

Financial Calendar

Upcoming Events Date
6 month unaudited financial statements of 2023 30 September 2023
audited annual financial statements of 2022 30 June 2023

Disclaimer

The following information does not constitute an public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.